Clene (CLNN) Price/OCF Ratio: History & Chart

Clene Inc.(CLNN)

Biotechnology · Salt Lake City, UT

$3.94+0.03 (+0.78%)

Delayed quote: Oct 6, 2026, 3:11 PM EDT

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Salt Lake City, UT

78 employees

clene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Etherington

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Clene Inc. (CLNN)	$50.35M	N/A	N/A	N/A	N/A
Envoy Medical, Inc. (COCH)vs ›	$50.37M	N/A	N/A	N/A	N/A
Dogwood Therapeutics, Inc. (DWTX)vs ›	$50.28M	N/A	N/A	N/A	N/A
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$51.03M	N/A	N/A	N/A	N/A
Tenax Therapeutics, Inc. (TENX)vs ›	$51.06M	N/A	N/A	N/A	N/A
INmune Bio, Inc. (INMB)vs ›	$49.58M	N/A	N/A	N/A	N/A
Precision Optics Corporation, Inc. (POCI)vs ›	$49.47M	N/A	73.59	628.92	487.62
TELA Bio, Inc. (TELA)vs ›	$49.44M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.51M	N/A	N/A	N/A	N/A
Sensus Healthcare, Inc. (SRTS)vs ›	$49.06M	N/A	43.78	43.71	50.95

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Clene Inc. (CLNN)

$50.35M

N/A

Envoy Medical, Inc. (COCH)vs ›

$50.37M

N/A

Dogwood Therapeutics, Inc. (DWTX)vs ›

$50.28M

N/A

Eloxx Pharmaceuticals, Inc. (ELOX)vs ›

$51.03M

N/A

Tenax Therapeutics, Inc. (TENX)vs ›

$51.06M

N/A

INmune Bio, Inc. (INMB)vs ›

$49.58M

N/A

Precision Optics Corporation, Inc. (POCI)vs ›

$49.47M

N/A

73.59

628.92

487.62

TELA Bio, Inc. (TELA)vs ›

$49.44M

N/A

eXoZymes, Inc. (EXOZ)vs ›

$51.51M

N/A

Sensus Healthcare, Inc. (SRTS)vs ›

$49.06M

N/A

43.78

43.71

50.95

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

CLNN Price/OCF Ratio Metrics

CLNN Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics